Evidence map›Paper›PMID 27190255›Full record

ArticleExperimental biology and medicine (Maywood, N.J.)2016

Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment.

Thananya Jinato, Natthaya Chuaypen, Witthaya Poomipak, Kesmanee Praianantathavorn, Jarika Makkoch, Rattanaporn Kiatbumrung, Kanisa Jampoka, Pisit Tangkijvanich, Sunchai Payungporn

Open access · greenAbstract read
In one paragraph

Article in Experimental biology and medicine (Maywood, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Thananya JinatoSystems Biology Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Natthaya ChuaypenDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand Research Unit of Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Witthaya PoomipakSystems Biology Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Kesmanee PraianantathavornDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Jarika MakkochDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Rattanaporn KiatbumrungDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Kanisa JampokaDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Pisit TangkijvanichDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand Research Unit of Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Sunchai PayungpornSystems Biology Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand Research Unit of Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand sp.medbiochemcu@gmail.com.
Chulalongkorn University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferons play important roles in defense mechanisms against viral infection, and thus interferon therapy has been a standard treatment in chronic hepatitis B patients. Interferons signaling pathways promote interferon-inducible genes including microRNAs. In this research, we aimed to determine microRNAs expression profiles in vitro and in vivo For in vitro model, Huh7 cells were transfected with or without hepatitis B virus plasmid for 6 h, and then treated with 100 ng of pegylated-interferon alpha-2a for 24 h. In vivo, we defined microRNAs expression profiles in pair-liver tissues of chronic hepatitis B patients in comparison between before and after treatment of pegylated-interferon alpha-2a for 48 weeks. Cellular small RNAs were extracted followed by library preparation. To determine microRNAs expression profiles, the next-generation sequencing was carried out on MiSeq platform (Illumina®). In vitro analysis demonstrated that microRNAs can be classified into up-regulated and down-regulated microRNAs in response to hepatitis B virus, interferon, and combination of hepatitis B virus and interferon. Moreover, in vivo analysis revealed microRNAs profiles in non-responders, responders without hepatitis B surface antigen clearance, and responders with hepatitis B surface antigen clearance. The target genes of the candidate microRNAs were determined in terms of roles in cellular pathways and immune response, which might be related to treatment in chronic hepatitis B patients. Results revealed that two down-regulated microRNAs including miR-185-5p and miR-186-5p were correlated in both in vitro and in vivo studies. These two microRNAs might be represented as specific hepatic microRNAs responding to hepatitis B virus and pegylated-interferon alpha-2a treatment, which may remarkable and attractive for further study involving in the association of their target genes and prediction of pegylated-interferon alpha-2a response. Interestingly, microRNAs expression patterns might be useful for understanding the response mechanism and serve as biomarkers for prediction of pegylated-interferon alpha-2a treatment response in patients with chronic hepatitis B.

Indexed as

AdultAntiviral AgentsFemaleGene Expression RegulationHepatitis B, ChronicHepatitis B virusHumansInterferon-alphaLiverMaleMicroRNAsPolyethylene GlycolsRecombinant ProteinsTranscriptomeAntiviral AgentsInterferon-alphaMicroRNAspeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteinshepatitis B virusinterferonmicroRNAnext-generation sequencing

Identifiers

PMID27190255
PMCPMC5027934
OpenAlexW2519552204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.